Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists

Askling, Johan

doi:10.1136/ard.2004.033993

Cited by 356 publications

(269 citation statements)

References 26 publications

Supporting

Mentioning

235

Contrasting

Unclassified

Order By: Relevance

“…Solid tumors-Studies of TNFα antagonist therapy in RA reveal no increased risk of solid tumors compared to the general population [99,102], corroborating results reported by the FDA. In contrast, a recent meta-analysis [82] reported higher rates of malignancies in RA patients treated with anti-TNF agents (29 of 3493 or 0.8%) compared to those on either placebo or active controls (3 of 1512 or 0.2%).…”

Section: Non-infectious Adverse Consequences Of Tnfα Antagonists Malisupporting

confidence: 79%

TNFα blockade in human diseases: An overview of efficacy and safety

Lin

Ziring

Desai

et al. 2008

Clinical Immunology

233

188

View full text Add to dashboard Cite

show abstract

Section: Non-infectious Adverse Consequences Of Tnfα Antagonists Malisupporting

confidence: 79%

TNFα blockade in human diseases: An overview of efficacy and safety

Lin

Ziring

Desai

et al. 2008

Clinical Immunology

233

188

View full text Add to dashboard Cite

show abstract

“…Another limitation would be that not all affected family members are hospitalized, in which case the numbers of hospitalizations would be decreased and would probably preferentially include only those patients with severe disease at presentation. In the case of RA, it has been estimated that up to 75% of Swedish patients have been hospitalized for RA at one time or another (29,30). A crude prevalence of hospitalization can be estimated by dividing the number of RA patients (47,361) by 8.5 million (the Swedish population over the study period minus the number of persons lacking family links), yielding a crude prevalence of hospitalization for RA of 0.56%; this is 80% of the assumed true population prevalence of RA (0.7%) in Sweden (31).…”

Section: Discussionmentioning

confidence: 99%

Familial associations of rheumatoid arthritis with autoimmune diseases and related conditions

Hemminki¹,

Li²,

Sundquist³

et al. 2009

Arthritis & Rheumatism

196

138

View full text Add to dashboard Cite

Objective. In the era of genome-wide association studies, familial risks are used to estimate disease heritability and the likelihood of candidate-gene identification. This study was undertaken to estimate associations of rheumatoid arthritis (RA) with any of 33 autoimmune diseases and related conditions among parents and offspring, singleton siblings, twins, and spouses.Methods. The Multigeneration Register in Sweden was used as a reliable source of information on Swedish families throughout the last century. Data on autoimmune diseases in individual family members were obtained through linkage to the Hospital Discharge Register. The standardized incidence ratio (SIR) was calculated as a measure of the relative risk of RA in family members of patients with RA or any of 33 other autoimmune diseases or related conditions, as compared with the relative risk of RA in those lacking an affected family member.

show abstract

“…Contraindications for using all classes of biologics are active infections, congestive heart failure, pregnancy and breast feeding [10][11][12] . Malignancies appear to be increased in RA, however there appears to be no additional increased risk in RA patients treated with biologics 13,14 . Infusion and injection site reactions are the commonest side effects.…”

Section: Biologic Use In Autoimmune Joint Diseasesmentioning

confidence: 98%